VIPoma risk factors: Difference between revisions
Jump to navigation
Jump to search
Homa Najafi (talk | contribs) No edit summary |
m (Bot: Removing from Primary care) |
||
| Line 14: | Line 14: | ||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
[[Category:Medicine]] | [[Category:Medicine]] | ||
[[Category:Oncology]] | [[Category:Oncology]] | ||
[[Category:Up-To-Date]] | [[Category:Up-To-Date]] | ||
[[Category:Endocrinology]] | [[Category:Endocrinology]] | ||
[[Category:Gastroenterology]] | [[Category:Gastroenterology]] | ||
Latest revision as of 00:40, 30 July 2020
|
VIPoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
VIPoma risk factors On the Web |
|
American Roentgen Ray Society Images of VIPoma risk factors |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Madhu Sigdel M.B.B.S.[2]Parminder Dhingra, M.D. [3] Homa Najafi, M.D.[4]
Overview
The most important risk factor in the development of VIPoma is a positive family history of multiple endocrine neoplasia type 1.
Risk Factors
- The most important risk factor in the development of VIPoma is a positive family history of multiple endocrine neoplasia type 1.[1]
- The most cases of VIPoma are sporadic whereas in 5% of cases are associated with MEN-1.
References
- ↑ Perry, R R; Vinik, A I (1995). "Clinical review 72: diagnosis and management of functioning islet cell tumors". The Journal of Clinical Endocrinology & Metabolism. 80 (8): 2273–2278. doi:10.1210/jcem.80.8.7629220. ISSN 0021-972X.